Evidence map›Paper›PMID 40040336›Full record

ArticleJournal of the American Geriatrics Society2025

Long-Term Exposure to Non-Steroidal Anti-Inflammatory Medication in Relation to Dementia Risk.

Ilse Vom Hofe, Bruno H Stricker, M Kamran Ikram, Frank J Wolters, M Arfan Ikram

Abstract read
In one paragraph

Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Redox modulation of the complement cascade contributes to synapse loss in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  15. Article
  16. Pharmacogenetic analyses in people with dementia in Northeast Germany.Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ilse Vom HofeDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-4212-7718
Bruno H StrickerDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
M Kamran IkramDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Frank J WoltersDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
M Arfan IkramDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Funding

Alzheimer NederlandBrain and Behavior Research Foundation 2020 NARSAD Young InvestigatorDirectorate-General XII, Science, Research, and DevelopmentErasmus Medisch CentrumErasmus Universiteit RotterdamMinisterie van Onderwijs, Cultuur en WetenschapMinisterie van Volksgezondheid, Welzijn en SportMunicipality of RotterdamResearch Institute for Diseases in the ElderlyVereniging Trustfonds Erasmus Universiteit Rotterdam 97030.2021.101.430/057/RBZonMw 73305095005
6 · The paper itself

Abstract

backgroundNon-steroidal anti-inflammatory (NSAID) medication could reduce dementia risk due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational studies and short-term randomized-controlled trials have been inconsistent, and duration and dose-response relationships are still unclear.

methodsWe included 11,745 dementia-free participants from the prospective population-based Rotterdam Study (59.5% female, mean age 66.2 years). NSAID use from 1991 was derived from pharmacy dispensing records, from which we determined cumulative duration and dose. We defined four mutually exclusive categories of cumulative use: non-use, short-term use (< 1 month), intermediate-term use (between 1 and 24 months), and long-term use (> 24 months). We determined the association with dementia risk until 2020 using Cox regression models, including NSAID use as a time-varying exposure. Models were adjusted for lifestyle factors, comorbidity, and comedication use. We repeated the analyses stratified by previously established amyloid-β lowering properties of different NSAIDs.

resultsDuring an average follow-up period of 14.5 years, a total of 9520 (81.1%) participants had used NSAIDs at any given time, and 2091 participants developed dementia. Use of NSAIDs was associated with lower dementia risk for long-term users (HR [95% CI]: 0.88 [0.84-0.91]), and a small increased risk with short-term use (HR [95% CI]: 1.04 [1.02-1.07]) or intermediate-term use (HR: 1.04 [1.02-1.06]). The cumulative dose of NSAIDs was not associated with decreased dementia risk (HR for ≤ 25th percentile: 1.06 [1.03-1.09], 26-50th percentile: 1.02 [0.99-1.05], 51-75th percentile: 1.03 [0.99-1.06], > 75th percentile: 0.99 [0.96-1.02]). Associations were somewhat stronger for long-term use of NSAIDs without known effects on amyloid-β than for amyloid-lowering NSAIDs (HR [95% CI]: 0.79 [0.74-0.85] versus 0.89 [0.85;0.93]).

conclusionLong-term NSAID use, but not cumulative dose, was associated with decreased dementia risk. This suggests that prolonged rather than intensive exposure to anti-inflammatory medication may hold potential for dementia prevention.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalDementiaAgedAged, 80 and overDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedNetherlandsProspective StudiesRisk FactorsTime FactorsAnti-Inflammatory Agents, Non-Steroidaldementianeuro‐inflammationnon‐steroidal anti‐inflammatory drugspopulation‐based

Identifiers

PMID40040336
PMCPMC12100699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.